论文部分内容阅读
OncoMed公司宣布更新其靶向切口蛋白2/3通道的单克隆抗体他瑞妥单抗(tarextumab,OMP-59R5)Ⅱ期临床ALPINE试验治疗胰腺癌和临床PINNACLE试验治疗小细胞肺癌的资料。靶向切口蛋白2/3受体的此药是全人源单抗。临床前研究提示此药有2个作用机制:①下调切口蛋白通路信号而具抗癌干细胞效应;②影响血管周细胞、基质细胞和肿瘤细胞的微环境。公司宣布从Ⅱ期临床ALPINE试验数据安全及监控委
OncoMed Inc. announced that it has updated its Phase II clinical ALPINE trial of monoclonal antibody targeting channel 2/3 of the nicking protein tarextumab (OMP-59R5) in the treatment of pancreatic and clinical PINNACLE for small cell lung cancer. This drug, which targets the nicked protein 2/3 receptor, is a fully human monoclonal antibody. Preclinical studies suggest that the drug has two mechanisms: ① downregulation of signal transduction pathway with anti-cancer stem cell effect; ② affect perivascular cells, stromal cells and tumor cells in the microenvironment. The company announced Phase II clinical ALPINE trial data safety and monitoring committee